It has been reported that p300 and serine/threonine kinase salt-inducible kinase 2 (SIK2) are major upstream regulators of carbohydrate-responsive element-binding protein (ChREBP) activity, which acts as a transcriptional activator of lipogenic and glycolytic genes and therefore, specific SIK2 activators and p300 inhibitors may be useful in pharmaceutical intervention of NAFLD/NASH [135]. The gene discussed is EP300; the disease is metabolic dysfunction-associated steatohepatitis.